Ads
related to: do statins reduce cardiovascular mortality
Search results
Results From The WOW.Com Content Network
New research from the University of Hong Kong found that statins effectively lowered the risk of cardiovascular and all-cause mortality among adults 60 years of age and older — including people ...
Statins have been studied for improving operative outcomes in cardiac and vascular surgery. [41] Mortality and adverse cardiovascular events were reduced in statin groups. [42] Older adults who receive statin therapy at time of discharge from the hospital after an inpatient stay have been studied. People with cardiac ischemia not previously on ...
In other words, as many as 4 million people in the U.S. who currently take statins for primary prevention — meaning they have not had a cardiovascular event such as a stroke or heart attack ...
Niacin, fibrates and CETP Inhibitors, while they may increase HDL cholesterol do not affect the risk of cardiovascular disease in those who are already on statins. [167] Fibrates lower the risk of cardiovascular and coronary events, but there is no evidence to suggest that they reduce all-cause mortality. [168]
These guidelines recommend statin therapy for adults between forty and seventy-five who have diabetes, high cholesterol levels, or an estimated 10-year atherosclerotic cardiovascular disease risk ...
Cardiovascular agents are drugs used to treat diseases associated with the heart or blood vessels. These medications are available for purchase only with a physician’s prescription . They include, but are not limited to, drugs that target hypertension ( antihypertensives ), hyperlipidemia ( antihyperlipidemics ) and blood clotting (blood ...
In addition to helping reduce LDL or “bad” cholesterol, statins do multiple jobs in the body simultaneously to assist in reducing your risk for heart disease, says Dr. Steinbaum, calling them ...
JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP).